568464
Last Update Posted: 2009-07-07
Recruiting has ended
All Genders accepted | 10 Years-65 Years |
10 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)
The purpose of this clinical trial was to evaluate the efficacy and tolerability of the sequential therapy of VCD/IE in the patients with ESFT.
80-90% patients of ESFT will develope disease progression during the period of local treatment (surgery or radiation). The survival has been improved in these 30 years due to chemotherapy. VCD/IE is widely used in the world for the patients with ESFT, but it is rarely used in China due to its high dosage.
Eligibility
Relevant conditions:
Ewing's Sarcoma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov